ID

34346

Description

GP2013 in Japanese Patients With CD20 Positive Low Tumor Burden Indolent B-cell Non-Hodgkin's Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT01933516

Link

https://clinicaltrials.gov/show/NCT01933516

Keywords

  1. 1/16/19 1/16/19 -
  2. 4/26/20 4/26/20 -
  3. 5/1/20 5/1/20 -
Copyright Holder

see on clinicaltrials.gov

Uploaded on

January 16, 2019

DOI

To request one please log in.

License

Creative Commons BY-NC 3.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Indolent B-cell Non-Hodgkin's Lymphoma NCT01933516

Eligibility Indolent B-cell Non-Hodgkin's Lymphoma NCT01933516

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
patient with cd20 positive low tumor burden indolent b-cell non- hodgkin's lymphoma.
Description

ID.1

Data type

boolean

patient with at least one measurable lesion.
Description

ID.2

Data type

boolean

patient with ecog performance status 0 or 1.
Description

ID.3

Data type

boolean

Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
patient who has received radiotherapy within the last 28 days prior to administration, or are not recovered from previous radiotherapy.
Description

ID.4

Data type

boolean

patient who has received immunotherapy, chemotherapy, antibodies and experimental treatment within the last 28 days prior to administration, or are not recovered from previous therapy.
Description

ID.5

Data type

boolean

patient who has mab therapy other than rituximab as prior line of therapy.
Description

ID.6

Data type

boolean

patient with evidence of any uncontrolled, acute or chronic active infection (viral, bacterial or fungal).
Description

ID.7

Data type

boolean

patient with any other malignancy within 5 years prior to date of screening, with the exception of adequately treated in situ carcinoma of the cervix uteri, basal or squamous cell carcinoma or nonmelanomatous skin cancer.
Description

ID.8

Data type

boolean

other protocol-defined inclusion/exclusion criteria may apply.
Description

ID.9

Data type

boolean

Similar models

Eligibility Indolent B-cell Non-Hodgkin's Lymphoma NCT01933516

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
patient with cd20 positive low tumor burden indolent b-cell non- hodgkin's lymphoma.
boolean
ID.2
Item
patient with at least one measurable lesion.
boolean
ID.3
Item
patient with ecog performance status 0 or 1.
boolean
Item Group
C0680251 (UMLS CUI)
ID.4
Item
patient who has received radiotherapy within the last 28 days prior to administration, or are not recovered from previous radiotherapy.
boolean
ID.5
Item
patient who has received immunotherapy, chemotherapy, antibodies and experimental treatment within the last 28 days prior to administration, or are not recovered from previous therapy.
boolean
ID.6
Item
patient who has mab therapy other than rituximab as prior line of therapy.
boolean
ID.7
Item
patient with evidence of any uncontrolled, acute or chronic active infection (viral, bacterial or fungal).
boolean
ID.8
Item
patient with any other malignancy within 5 years prior to date of screening, with the exception of adequately treated in situ carcinoma of the cervix uteri, basal or squamous cell carcinoma or nonmelanomatous skin cancer.
boolean
ID.9
Item
other protocol-defined inclusion/exclusion criteria may apply.
boolean

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial